NEUROSENSE THERAPEUTICS LTD

Neurosense Therapeutics’ stock rallies 7% after early‑stage ALS data, but its price remains far below the 200‑day MA and has dropped 64% since March. Investors eye a Q1‑2027 data readout that could spark a breakout above $3.

Neurosense Therapeutics slides 10% as investors await pivotal ALS trial data—discover how clinical milestones could reverse the steep decline and reshape its market value.

Neurosense Therapeutics shares plunged 13.2% to $2.39, a steep drop below its 200‑day SMA and 52‑week low, amid broader volatility in neuro‑drug stocks.